Symbols / GLUE
GLUE Chart
About
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.46B |
| Enterprise Value | 899.82M | Income | 20.95M | Sales | 181.54M |
| Book/sh | 3.98 | Cash/sh | 6.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 147 | IPO | — |
| P/E | 60.03 | Forward P/E | -13.91 | PEG | — |
| P/S | 8.07 | P/B | 4.83 | P/C | — |
| EV/EBITDA | 53.43 | EV/Sales | 4.96 | Quick Ratio | 6.45 |
| Current Ratio | 6.54 | Debt/Eq | 16.34 | LT Debt/Eq | — |
| EPS (ttm) | 0.32 | EPS next Y | -1.38 | EPS Growth | — |
| Revenue Growth | 38.50% | Earnings | 2026-03-19 | ROA | 1.37% |
| ROE | 9.28% | ROIC | — | Gross Margin | 28.08% |
| Oper. Margin | -258.26% | Profit Margin | 11.54% | Shs Outstand | 76.24M |
| Shs Float | 46.36M | Short Float | 12.54% | Short Ratio | 3.05 |
| Short Interest | — | 52W High | 25.77 | 52W Low | 3.50 |
| Beta | 1.62 | Avg Volume | 1.61M | Volume | 681.67K |
| Target Price | $33.80 | Recom | Strong_buy | Prev Close | $19.51 |
| Price | $19.21 | Change | -1.54% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$33.80
Mean price target
2. Current target
$19.20
Latest analyst target
3. DCF / Fair value
$11.47
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$19.20
Low
$30.00
High
$37.00
Mean
$33.80
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-14 | reit | Piper Sandler | Overweight → Overweight | $37 |
| 2026-01-08 | main | Wells Fargo | Overweight → Overweight | $30 |
| 2026-01-08 | main | Guggenheim | Buy → Buy | $34 |
| 2025-12-16 | up | Wells Fargo | Equal-Weight → Overweight | $22 |
| 2025-11-07 | main | Wells Fargo | Equal-Weight → Equal-Weight | $13 |
| 2025-03-21 | main | Wells Fargo | Equal-Weight → Equal-Weight | $10 |
| 2025-03-21 | main | Wedbush | Outperform → Outperform | $17 |
| 2025-03-12 | init | LifeSci Capital | — → Outperform | $19 |
| 2024-12-19 | down | Wells Fargo | Overweight → Equal-Weight | $11 |
| 2024-09-12 | reit | Wedbush | Outperform → Outperform | $11 |
| 2024-08-12 | main | Wells Fargo | Overweight → Overweight | $17 |
| 2024-06-28 | reit | Piper Sandler | Overweight → Overweight | $16 |
| 2024-05-22 | reit | Wedbush | Outperform → Outperform | $11 |
| 2024-02-15 | init | Wedbush | — → Outperform | $11 |
| 2023-10-19 | main | JP Morgan | Overweight → Overweight | $11 |
| 2023-08-11 | reit | Credit Suisse | Neutral → Neutral | $11 |
| 2023-05-12 | reit | Credit Suisse | Neutral → Neutral | $11 |
| 2023-03-17 | main | Credit Suisse | — → Neutral | $11 |
| 2023-01-03 | up | Wells Fargo | Equal-Weight → Overweight | $19 |
| 2022-10-13 | init | UBS | — → Buy | $22 |
- Top Executive Makes Notable Move in Monte Rosa Therapeutics Stock - TipRanks Wed, 25 Feb 2026 07
- Biotech firm Monte Rosa lines up three investor talks in March - Stock Titan Mon, 23 Feb 2026 12
- Stick chemistry: High-throughput method for finding new molecular glues - C&EN hu, 19 Feb 2026 19
- Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by GSA Capital Partners LLP - MarketBeat Fri, 20 Feb 2026 12
- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? - Yahoo Finance Wed, 29 Oct 2025 07
- Why Did GLUE Stock Surge Over 50% In Premarket Today? - Stocktwits Wed, 07 Jan 2026 08
- GLUE Stock Price and Chart — NASDAQ:GLUE - TradingView Wed, 12 Nov 2025 08
- The Market Doesn't Like What It Sees From Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Revenues Yet As Shares Tumble 26% - simplywall.st Sat, 14 Feb 2026 08
- Monte Rosa stock rises after pact with Novartis (GLUE:NASDAQ) - Seeking Alpha Mon, 15 Sep 2025 07
- 'Stick and glue' method enables more precise biomolecule tracking in cells - Phys.org Fri, 28 Nov 2025 08
- GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Yahoo Finance hu, 08 Jan 2026 08
- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Drop in Short Interest - MarketBeat Sat, 31 Jan 2026 08
- Here’s Why Monte Rosa Therapeutics Stock (GLUE) Rocketed Today - TipRanks Wed, 07 Jan 2026 08
- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock? - simplywall.st ue, 16 Sep 2025 07
- GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount - Stocktwits Fri, 09 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5466 | 128373 | — | Sale at price 23.24 - 24.57 per share. | WARMUTH MARKUS M.D. | Chief Executive Officer | — | 2026-01-07 00:00:00 | D |
| 1 | 3155 | 47861 | — | Sale at price 15.17 per share. | TOWNSON SHARON | Officer | — | 2026-01-05 00:00:00 | D |
| 2 | 10135 | 153748 | — | Sale at price 15.17 per share. | WARMUTH MARKUS M.D. | Chief Executive Officer | — | 2026-01-05 00:00:00 | D |
| 3 | 3155 | 47861 | — | Sale at price 15.17 per share. | JANKU FILIP | Officer | — | 2026-01-05 00:00:00 | D |
| 4 | 3155 | 47861 | — | Sale at price 15.17 per share. | NICKSON PHILIP | Officer | — | 2026-01-05 00:00:00 | D |
| 5 | 1039 | 15762 | — | Sale at price 15.17 per share. | DUNN EDMUND | Officer | — | 2026-01-05 00:00:00 | D |
| 6 | 2629 | 39882 | — | Sale at price 15.17 per share. | CHAMPOUX JENNIFER | Chief Operating Officer | — | 2026-01-05 00:00:00 | D |
| 7 | 35000 | — | — | Stock Award(Grant) at price 0.00 per share. | TOWNSON SHARON | Officer | — | 2026-01-02 00:00:00 | D |
| 8 | 90000 | — | — | Stock Award(Grant) at price 0.00 per share. | WARMUTH MARKUS M.D. | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 9 | 31000 | — | — | Stock Award(Grant) at price 0.00 per share. | JANKU FILIP | Officer | — | 2026-01-02 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 87.36K | -217.77K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -73.41M | -136.05M | -108.76M | -70.59M |
| TotalUnusualItems | 416.00K | -1.04M | 119.00K | -162.00K |
| TotalUnusualItemsExcludingGoodwill | 416.00K | -1.04M | 119.00K | -162.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -72.70M | -135.35M | -108.50M | -73.96M |
| ReconciledDepreciation | 8.12M | 6.22M | 3.75M | 2.13M |
| EBITDA | -72.99M | -137.09M | -108.64M | -70.75M |
| EBIT | -81.11M | -143.31M | -112.38M | -72.88M |
| NetInterestIncome | 10.57M | 9.33M | 3.76M | 46.00K |
| InterestIncome | 10.57M | 9.33M | 3.76M | 46.00K |
| NormalizedIncome | -73.03M | -134.53M | -108.62M | -73.80M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -72.70M | -135.35M | -108.50M | -73.96M |
| TotalExpenses | 156.73M | 143.31M | 112.38M | 72.88M |
| TotalOperatingIncomeAsReported | -81.11M | -143.31M | -112.38M | -72.88M |
| DilutedAverageShares | 61.51M | 51.40M | 47.23M | 25.00M |
| BasicAverageShares | 61.51M | 51.40M | 47.23M | 25.00M |
| DilutedEPS | -1.18 | -2.63 | -2.30 | -2.96 |
| BasicEPS | -1.18 | -2.63 | -2.30 | -2.96 |
| DilutedNIAvailtoComStockholders | -72.70M | -135.35M | -108.50M | -73.96M |
| NetIncomeCommonStockholders | -72.70M | -135.35M | -108.50M | -73.96M |
| NetIncome | -72.70M | -135.35M | -108.50M | -73.96M |
| NetIncomeIncludingNoncontrollingInterests | -72.70M | -135.35M | -108.50M | -73.96M |
| NetIncomeContinuousOperations | -72.70M | -135.35M | -108.50M | -73.96M |
| TaxProvision | 2.57M | 338.00K | 0.00 | |
| PretaxIncome | -70.13M | -135.01M | -108.50M | -73.96M |
| OtherIncomeExpense | 416.00K | -1.04M | 119.00K | -1.12M |
| OtherNonOperatingIncomeExpenses | -960.00K | |||
| SpecialIncomeCharges | 0.00 | 24.00K | 109.00K | 0.00 |
| GainOnSaleOfPPE | 0.00 | 24.00K | 109.00K | 0.00 |
| GainOnSaleOfSecurity | 416.00K | -1.06M | 10.00K | -162.00K |
| NetNonOperatingInterestIncomeExpense | 10.57M | 9.33M | 3.76M | 46.00K |
| InterestIncomeNonOperating | 10.57M | 9.33M | 3.76M | 46.00K |
| OperatingIncome | -81.11M | -143.31M | -112.38M | -72.88M |
| OperatingExpense | 156.73M | 143.31M | 112.38M | 72.88M |
| ResearchAndDevelopment | 121.56M | 111.27M | 85.06M | 57.16M |
| SellingGeneralAndAdministration | 35.17M | 32.04M | 27.32M | 15.73M |
| GeneralAndAdministrativeExpense | 35.17M | 32.04M | 27.32M | 15.73M |
| OtherGandA | 13.02M | 12.39M | 11.94M | 6.24M |
| SalariesAndWages | 22.15M | 19.65M | 15.39M | 9.48M |
| TotalRevenue | 75.62M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 75.62M | 0.00 | 0.00 | 0.00 |
| Line Item | 2022-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 122.27K | |||
| OrdinarySharesNumber | 61.51M | 50.14M | 49.32M | 46.54M |
| ShareIssued | 61.51M | 50.14M | 49.45M | 46.54M |
| TotalDebt | 42.72M | 46.04M | 47.00M | 0.00 |
| TangibleBookValue | 222.94M | 179.25M | 271.41M | 347.51M |
| InvestedCapital | 222.94M | 179.25M | 271.41M | 347.51M |
| WorkingCapital | 220.49M | 189.62M | 250.32M | 332.03M |
| NetTangibleAssets | 222.94M | 179.25M | 271.41M | 347.51M |
| CapitalLeaseObligations | 42.72M | 46.04M | 47.00M | 0.00 |
| CommonStockEquity | 222.94M | 179.25M | 271.41M | 347.51M |
| TotalCapitalization | 222.94M | 179.25M | 271.41M | 347.51M |
| TotalEquityGrossMinorityInterest | 222.94M | 179.25M | 271.41M | 347.51M |
| StockholdersEquity | 222.94M | 179.25M | 271.41M | 347.51M |
| GainsLossesNotAffectingRetainedEarnings | -3.36M | -2.72M | -1.75M | -2.02M |
| OtherEquityAdjustments | -3.36M | -2.72M | -1.75M | -2.02M |
| RetainedEarnings | -438.59M | -365.89M | -230.54M | -122.03M |
| AdditionalPaidInCapital | 664.87M | 547.86M | 503.70M | 471.57M |
| CapitalStock | 6.00K | 5.00K | 5.00K | 5.00K |
| CommonStock | 6.00K | 5.00K | 5.00K | 5.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 215.80M | 124.50M | 70.98M | 18.81M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 58.85M | 77.91M | 45.41M | 2.18M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | 0.00 | 0.00 |
| EmployeeBenefits | 3.70M | 2.71M | 1.53M | 2.18M |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 3.70M | 2.71M | 1.53M | 2.18M |
| NonCurrentDeferredLiabilities | 16.15M | 32.32M | 0.00 | |
| NonCurrentDeferredRevenue | 16.15M | 32.32M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 39.00M | 42.88M | 43.87M | 0.00 |
| LongTermCapitalLeaseObligation | 39.00M | 42.88M | 43.87M | 0.00 |
| CurrentLiabilities | 156.95M | 46.59M | 25.57M | 16.64M |
| OtherCurrentLiabilities | 3.35M | 1.67M | 5.02M | 840.00K |
| CurrentDeferredLiabilities | 117.23M | 17.68M | 0.00 | |
| CurrentDeferredRevenue | 117.23M | 17.68M | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 3.71M | 3.16M | 3.13M | |
| CurrentCapitalLeaseObligation | 3.71M | 3.16M | 3.13M | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 8.22M | 7.59M | 5.62M | 4.30M |
| PayablesAndAccruedExpenses | 24.43M | 16.49M | 11.80M | 11.49M |
| CurrentAccruedExpenses | 7.21M | 5.34M | 3.94M | 4.94M |
| Payables | 17.21M | 11.15M | 7.86M | 6.56M |
| AccountsPayable | 17.21M | 11.15M | 7.86M | 6.56M |
| TotalAssets | 438.73M | 303.75M | 342.39M | 366.33M |
| TotalNonCurrentAssets | 61.29M | 67.54M | 66.50M | 17.66M |
| OtherNonCurrentAssets | 4.98M | 4.93M | 4.60M | 5.34M |
| NetPPE | 56.31M | 62.61M | 61.91M | 12.32M |
| AccumulatedDepreciation | -20.36M | -12.24M | -6.25M | -2.70M |
| GrossPPE | 76.68M | 74.86M | 68.16M | 15.03M |
| Leases | 22.39M | 20.89M | 2.66M | 1.12M |
| ConstructionInProgress | 64.00K | 924.00K | 12.01M | 852.00K |
| OtherProperties | 51.87M | 50.89M | 52.60M | 12.31M |
| MachineryFurnitureEquipment | 2.35M | 2.15M | 887.00K | 742.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 377.44M | 236.21M | 275.89M | 348.67M |
| OtherCurrentAssets | 5.12M | 3.29M | 4.44M | 2.60M |
| RestrictedCash | 0.00 | 960.00K | 0.00 | |
| PrepaidAssets | 2.60M | |||
| Receivables | 173.00K | 505.00K | 7.66M | 0.00 |
| OtherReceivables | 173.00K | 505.00K | 7.66M | |
| CashCashEquivalentsAndShortTermInvestments | 372.15M | 232.41M | 262.83M | 346.07M |
| OtherShortTermInvestments | 147.90M | 104.31M | 207.91M | 0.00 |
| CashAndCashEquivalents | 224.25M | 128.10M | 54.91M | 346.07M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 38.01M | -62.84M | -105.38M | -69.09M |
| RepurchaseOfCapitalStock | -641.00K | -116.00K | ||
| IssuanceOfCapitalStock | 944.00K | 0.00 | 20.05M | 380.75M |
| CapitalExpenditure | -3.99M | -19.04M | -12.91M | -9.73M |
| EndCashPosition | 229.12M | 132.68M | 60.19M | 351.41M |
| BeginningCashPosition | 132.68M | 60.19M | 351.41M | 42.86M |
| ChangesInCash | 96.44M | 72.49M | -291.22M | 308.55M |
| FinancingCashFlow | 98.89M | 27.49M | 20.47M | 377.56M |
| CashFlowFromContinuingFinancingActivities | 98.89M | 27.49M | 20.47M | 377.56M |
| NetOtherFinancingCharges | 47.00M | -116.00K | -364.00K | -3.34M |
| ProceedsFromStockOptionExercised | 51.59M | 27.61M | 775.00K | 149.00K |
| NetPreferredStockIssuance | 0.00 | 143.00M | ||
| PreferredStockIssuance | 0.00 | 143.00M | ||
| NetCommonStockIssuance | 303.00K | -116.00K | 20.05M | 237.75M |
| CommonStockPayments | -641.00K | -116.00K | ||
| CommonStockIssuance | 944.00K | 0.00 | 20.05M | 237.75M |
| InvestingCashFlow | -44.45M | 88.80M | -219.22M | -9.65M |
| CashFlowFromContinuingInvestingActivities | -44.45M | 88.80M | -219.22M | -9.65M |
| NetInvestmentPurchaseAndSale | -40.46M | 107.78M | -206.42M | 0.00 |
| SaleOfInvestment | 189.90M | 210.93M | 178.00M | 0.00 |
| PurchaseOfInvestment | -230.36M | -103.15M | -384.42M | 0.00 |
| NetPPEPurchaseAndSale | -3.99M | -18.98M | -12.80M | -9.65M |
| SaleOfPPE | 0.00 | 62.00K | 109.00K | 79.00K |
| PurchaseOfPPE | -3.99M | -19.04M | -12.91M | -9.73M |
| OperatingCashFlow | 42.00M | -43.80M | -92.47M | -59.36M |
| CashFlowFromContinuingOperatingActivities | 42.00M | -43.80M | -92.47M | -59.36M |
| ChangeInWorkingCapital | 91.40M | 72.47M | -2.13M | 6.29M |
| ChangeInOtherWorkingCapital | 82.22M | 60.18M | -107.00K | 1.11M |
| ChangeInPayablesAndAccruedExpense | 10.44M | 9.31M | 287.00K | 5.88M |
| ChangeInAccruedExpense | 4.18M | 3.56M | 1.03M | 6.59M |
| ChangeInPayable | 6.25M | 5.76M | -744.00K | -706.00K |
| ChangeInAccountPayable | 6.25M | 5.76M | -744.00K | -706.00K |
| ChangeInPrepaidAssets | -1.59M | 1.08M | -2.13M | -704.00K |
| ChangeInReceivables | 332.00K | 1.90M | -187.00K | 0.00 |
| OtherNonCashItems | 4.81M | 960.00K | ||
| StockBasedCompensation | 18.13M | 16.67M | 11.66M | 5.20M |
| AmortizationOfSecurities | -2.95M | -3.91M | -1.95M | 0.00 |
| DepreciationAmortizationDepletion | 8.12M | 6.22M | 3.75M | 2.13M |
| DepreciationAndAmortization | 8.12M | 6.22M | 3.75M | 2.13M |
| Depreciation | 8.12M | 6.22M | 3.75M | 2.13M |
| OperatingGainsLosses | 107.00K | -109.00K | 17.00K | |
| GainLossOnInvestmentSecurities | 131.00K | |||
| GainLossOnSaleOfPPE | 0.00 | -24.00K | -109.00K | 17.00K |
| NetIncomeFromContinuingOperations | -72.70M | -135.35M | -108.50M | -73.96M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GLUE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|